The immunophenotypic study showed blasts of myeloid lineage, of which 5% corresponded to low CBF/SSC, low CD45, weak CD34, CD13, CD15 and CD19 moderate CD19 granulocytic CD13, CD13 CD19, CD19 and CD16, CD33 intermediate CD17 cells,